Comparing PSMA PET scans for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study uses two different PSMA PET/CT tracers to see how well they detect cancer in patients with advanced prostate cancer that has spread or stopped responding to hormone therapy. The goal is to improve imaging for better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has spread to other parts of the body (metastatic) and is either still responding to hormone therapy or has stopped responding.
- You are able to undergo a PET/CT scan with a special radioactive tracer that targets prostate cancer cells.
- Your blood counts, kidney function, and liver function are within acceptable limits.
- You are expected to live at least 6 more months.
- You agree to use effective contraception and avoid sperm donation during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of PET scans—one using a new tracer called [18F]F-PSMA-N5 and another using an existing tracer called [68Ga]Ga-PSMA-11—to see which is better at finding prostate cancer, including early signs of recurrence. If you have or are suspected of having prostate cancer, this study may help determine how advanced the disease is.
This trial compares two types of PET/CT scans (using different radioactive tracers) to see which is better at finding prostate cancer, tracking its return, or spotting spread. It's for people with prostate cancer or those being checked for recurrence after treatment.
This trial tests a high-precision scan that uses a prostate cancer marker to show where cancer may be. The goal is to use the scan results to better plan treatment, especially around surgery and lymph nodes, in certain patients with prostate cancer.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.